The asset purchase, announced April 29, brings together diagnostic infrastructure, DNA methylation datasets and direct-to-consumer interventions under one platform.
Combined dataset seen as key asset
Both companies point to data scale as a central component of the deal. Infinite Epigenetics, through its TruDiagnostic business, has built its platform around biological age testing, while Tally Health contributes a consumer base and testing program anchored by its TallyAge product.
“The primary unlock is statistical power and real-world relevance, [and] by combining datasets, we now have the largest DNA methylation database in the private sector,” Matthew Dawson, CEO of Infinite Epigenetics and TruDiagnostic, told NutraIngredients.
He said the expanded dataset allows the company to validate signals across broader populations and to identify smaller effects associated with interventions such as nutrition and supplementation.
Vertical integration across testing and supplements
Tally Health’s model combines at-home epigenetic testing with supplement recommendations and lifestyle guidance. That offering will now sit alongside Infinite Epigenetics’ laboratory and analytics capabilities, including its CLIA-certified lab and existing testing platforms.
“With Infinite Epigenetics’ infrastructure and Tally’s established products, we are creating a fully integrated platform operating across the full stack: measurement, interpretation and intervention,” Dawson said.
In a press statement, Tally Health confirmed that the combined platform will be used to link testing data with downstream interventions, including supplements, and to evaluate outcomes over time.
Focus on product development and validation
Executives from both companies pointed to product development as an area of focus following the integration.
Dawson said increased access to biological data will allow for more iterative approaches to formulation, with testing and intervention more closely connected.
“As measurement becomes more accessible and more reliable, product development will increasingly be informed by biological data rather than assumptions or generalized claims,” he said.
He added that larger datasets enable examination of how products perform across different groups and conditions, rather than relying on narrower study designs.
Tally Health to operate as standalone brand
Tally Health will continue to operate as a standalone consumer brand, with its existing products and customer experience remaining in place following the acquisition.
“From a consumer perspective, continuity is key—our brand, our products, and the overall experience remain intact,” Melanie Goldey, CEO of Tally Health, told NI.
She said that integration with Infinite Epigenetics will expand the platform’s scientific capabilities, including access to laboratory infrastructure and larger datasets.
“With direct access to CLIA-certified lab infrastructure and a much larger epigenetic dataset, we can move from hypothesis-driven formulation to data-informed iteration,” Goldey said.
The company, co-founded by Harvard Medical School geneticist Dr. David Sinclair, has focused on combining epigenetic testing with personalized interventions, including supplements.
Supplier relationships and evidence expectations
Goldey said the company will continue to work with ingredient suppliers and manufacturing partners, with an emphasis on evidence and collaboration.
“We’re always focused on partners who meet a higher standard around evidence, transparency, and collaboration,” she said.
This includes participation in validation efforts and alignment on quality and traceability standards, according to the company.
Both executives indicated that the integration will be used to evaluate how interventions, including supplements, influence biological aging over time, using the combined dataset.
“It’s already beginning, but this kind of scale accelerates the timeline meaningfully, [and] with larger datasets and tighter integration between testing and intervention, we can move toward continuous optimization,” Dawson added.
